# Nir Kalkstein

> Nir Kalkstein is a seed investor at Medial EarlySign backing Health Care. See 2 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Medial EarlySign
- Location: Kfar Malal, Israel
- Total investments: 2
- Last investment: Mar 2018
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/nir-kalkstein-3512b2/

Nir Kalkstein is an entrepreneur, a data scientist and a recognized expert in Big Data and machine learning algorithms. Nir co-founded Final, one of the most successful algo-trading companies worldwide. In 2009 He co-founded Medial with the vision of creating data-driven best-in-class predicative tools that provide physicians with actionableinsights to save lives. Nir has devoted significant intellectual and financial resources to support the ongoing success of the research for the Company, initially as the sole financier, and is committed to reinvesting his future profits into further research. Nir holds a BSc in Electrical Engineering from the Israeli Technion Institute of Technology.

## Contacts

5 contacts available for Nir Kalkstein: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/nir-kalkstein?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Machine Learning | 2 | 100% |
| Artificial Intelligence | 2 | 100% |
| Big Data | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Medial EarlySign | Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s ofmillions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities | $30M | Series B | Mar 06, 2018 |  |
| Nucleai | Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $5M | Seed | Mar 05, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 1 deal together
- [Horizons Ventures](https://shizune.co/investors/profile/horizons-ventures) — VC Fund, 1 deal together
- [Vertex Ventures Israel](https://shizune.co/investors/profile/vertex-ventures-israel) — VC Fund, 1 deal together

## About Medial EarlySign

VC Fund · Hod Hasharon, Israel

Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s ofmillions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities

4 contacts available at Medial EarlySign.

| Name | Title | Profile |
| --- | --- | --- |
| Nir Kalkstein | Co-founder & CTO | https://shizune.co/investors/profile/nir-kalkstein |
| Avi Shoshan | Head of Data Science | — |
| Darrell Atkin | Vice President Marketing | — |
| Ori Geva | Co-founder & President of Commercial Strategy | — |

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors in Middle East](https://shizune.co/investors/health-care-angel-investors-middle-east)
- [Health Care Angel Investors in Israel](https://shizune.co/investors/health-care-angel-investors-israel)
- [Artificial intelligence Angel Investors in Middle East](https://shizune.co/investors/artificial-intelligence-angel-investors-middle-east)
- [Artificial intelligence Angel Investors in Israel](https://shizune.co/investors/artificial-intelligence-angel-investors-israel)
- [Machine Learning Angel Investors in Israel](https://shizune.co/investors/machine-learning-angel-investors-israel)

## FAQ

### What does Nir Kalkstein invest in?

Nir Kalkstein invests primarily in Health Care, Machine Learning and Artificial Intelligence startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nir Kalkstein?

Public channels for Nir Kalkstein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Nir Kalkstein last invest?

The most recent investment recorded for Nir Kalkstein closed in Mar 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co